Piramal Pharma - News

NSE: PPLPHARMA | BSE: 543635

₹191.07

₹-3.92 (-2.01%)

As on 23-Oct-2026IST

Market cap

₹25,409 Cr

Revenue (TTM)

₹9,205 Cr

P/E Ratio

--

P/B Ratio

3.2

Div. Yield

0 %

Quarterly Updates

2026

2025

2024

2023

2022

Annual Reports

Annual Reports

2026

Annual Reports

2025

Annual Reports

2024

Annual Reports

2023

Announcements

View Announcements

Recent

Important

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

16-Oct-2026

Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended 30Th September 2026

16-Oct-2026

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private Limited

01-Oct-2026

Clarification On News Item Which Appeared In The'Www.Thehindubusinessline.Com' Dated September 30 2026 Captioned 'Ontario Contributes $1.7 Million Investment To Advance Life Sciences Innovation At Piramal Pharma'S Aurora Facility.'

01-Oct-2026

Announcement under Regulation 30 (LODR)-Change in Management

30-Sep-2026

Announcement under Regulation 30 (LODR)-Change in Management

30-Sep-2026

Clarification sought from Piramal Pharma Ltd

30-Sep-2026

Closure of Trading Window

29-Sep-2026

Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015

29-Sep-2026

Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating -Niche NinetyNine Capability And Certifications (OPC) Private Limited

18-Sep-2026